REPORT ID 5065

United States Interleukin 1 (IL1) Market Report 2017

Publish Date
20-Dec-17
Pages
106
Format
Electronic (PDF)

In this report, the United States Interleukin 1 (IL1) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Interleukin 1 (IL1) in these regions, from 2012 to 2022 (forecast).

United States Interleukin 1 (IL1) market competition by top manufacturers/players, with Interleukin 1 (IL1) sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Optimum Therapeutics LLC
    Orphit SAS
    Peptinov SAS
    AbbVie Inc
    Swedish Orphan Biovitrum AB
    TWi Biotechnology Inc
    XBiotech Inc
    Cell Medica Ltd
    Exicure Inc
    Immune Response BioPharma Inc
    Novartis AG
    Omnitura Therapeutics Inc
    Opsona Therapeutics Ltd
    Anacor Pharmaceuticals Inc
    Apexigen Inc
    R Pharm
    Regeneron Pharmaceuticals Inc

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    APX-002
    Canakinumab
    Diacerein CR
    IR-1000
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Esophageal Cancer
    Fallopian Tube Cancer
    Bladder Cancer
    Bechcer Disease
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Interleukin 1 (IL1) Market Report 2017
1 Interleukin 1 (IL1) Overview
    1.1 Product Overview and Scope of Interleukin 1 (IL1)
    1.2 Classification of Interleukin 1 (IL1) by Product Category
        1.2.1 United States Interleukin 1 (IL1) Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Interleukin 1 (IL1) Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 APX-002
        1.2.4 Canakinumab
        1.2.5 Diacerein CR
        1.2.6 IR-1000
        1.2.7 Others
    1.3 United States Interleukin 1 (IL1) Market by Application/End Users
        1.3.1 United States Interleukin 1 (IL1) Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Esophageal Cancer
        1.3.3 Fallopian Tube Cancer
        1.3.4 Bladder Cancer
        1.3.5 Bechcer Disease
        1.3.6 Others
    1.4 United States Interleukin 1 (IL1) Market by Region
        1.4.1 United States Interleukin 1 (IL1) Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Interleukin 1 (IL1) Status and Prospect (2012-2022)
        1.4.3 Southwest Interleukin 1 (IL1) Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Interleukin 1 (IL1) Status and Prospect (2012-2022)
        1.4.5 New England Interleukin 1 (IL1) Status and Prospect (2012-2022)
        1.4.6 The South Interleukin 1 (IL1) Status and Prospect (2012-2022)
        1.4.7 The Midwest Interleukin 1 (IL1) Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Interleukin 1 (IL1) (2012-2022)
        1.5.1 United States Interleukin 1 (IL1) Sales and Growth Rate (2012-2022)
        1.5.2 United States Interleukin 1 (IL1) Revenue and Growth Rate (2012-2022)

2 United States Interleukin 1 (IL1) Market Competition by Players/Suppliers
    2.1 United States Interleukin 1 (IL1) Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Interleukin 1 (IL1) Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Interleukin 1 (IL1) Average Price by Players/Suppliers (2012-2017)
    2.4 United States Interleukin 1 (IL1) Market Competitive Situation and Trends
        2.4.1 United States Interleukin 1 (IL1) Market Concentration Rate
        2.4.2 United States Interleukin 1 (IL1) Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Interleukin 1 (IL1) Manufacturing Base Distribution, Sales Area, Product Type

3 United States Interleukin 1 (IL1) Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Interleukin 1 (IL1) Sales and Market Share by Region (2012-2017)
    3.2 United States Interleukin 1 (IL1) Revenue and Market Share by Region (2012-2017)
    3.3 United States Interleukin 1 (IL1) Price by Region (2012-2017)

4 United States Interleukin 1 (IL1) Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Interleukin 1 (IL1) Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Interleukin 1 (IL1) Revenue and Market Share by Type (2012-2017)
    4.3 United States Interleukin 1 (IL1) Price by Type (2012-2017)
    4.4 United States Interleukin 1 (IL1) Sales Growth Rate by Type (2012-2017)

5 United States Interleukin 1 (IL1) Sales (Volume) by Application (2012-2017)
    5.1 United States Interleukin 1 (IL1) Sales and Market Share by Application (2012-2017)
    5.2 United States Interleukin 1 (IL1) Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Interleukin 1 (IL1) Players/Suppliers Profiles and Sales Data
    6.1 Optimum Therapeutics LLC
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Optimum Therapeutics LLC Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Orphit SAS
        6.2.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Orphit SAS Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Peptinov SAS
        6.3.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Peptinov SAS Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 AbbVie Inc
        6.4.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 AbbVie Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Swedish Orphan Biovitrum AB
        6.5.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 TWi Biotechnology Inc
        6.6.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 TWi Biotechnology Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 XBiotech Inc
        6.7.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 XBiotech Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Cell Medica Ltd
        6.8.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Cell Medica Ltd Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Exicure Inc
        6.9.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Exicure Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Immune Response BioPharma Inc
        6.10.2 Interleukin 1 (IL1) Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Immune Response BioPharma Inc Interleukin 1 (IL1) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Novartis AG
    6.12 Omnitura Therapeutics Inc
    6.13 Opsona Therapeutics Ltd
    6.14 Anacor Pharmaceuticals Inc
    6.15 Apexigen Inc
    6.16 R Pharm
    6.17 Regeneron Pharmaceuticals Inc

7 Interleukin 1 (IL1) Manufacturing Cost Analysis
    7.1 Interleukin 1 (IL1) Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Interleukin 1 (IL1)

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Interleukin 1 (IL1) Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Interleukin 1 (IL1) Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Interleukin 1 (IL1) Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Interleukin 1 (IL1) Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Interleukin 1 (IL1) Sales Volume Forecast by Type (2017-2022)
    11.3 United States Interleukin 1 (IL1) Sales Volume Forecast by Application (2017-2022)
    11.4 United States Interleukin 1 (IL1) Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer